Protect IVF Act

Bill Number

S. 2035

Origin Chamber

Senate

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-06-11: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Last Updated

2025-12-19T12:03:16Z

AI-Generated Summary

Purpose

The "Protect IVF Act" aims to establish federal statutory rights ensuring that individuals can access fertility treatments, health care providers can offer them, insurers can cover them, and manufacturers can produce related drugs and devices without undue state restrictions. It seeks to prevent states from imposing limitations on assisted reproductive technologies (like in vitro fertilization, or IVF) that deviate from established medical standards, thereby promoting patient choice, evidence-based care, and the ability to achieve healthy pregnancies.

Key Provisions

• Definitions:
• "Fertility treatment" broadly includes services like egg/sperm/embryo preservation, artificial insemination, IVF, genetic testing of embryos, fertility medications, gamete (egg or sperm) donation, and other related procedures or referrals deemed appropriate by the Secretary of Health and Human Services.
• "Health care provider" covers doctors, nurses, pharmacists, and others involved in delivering these services, even if state licensing is affected by providing fertility care.
• "Widely accepted and evidence-based medical standards of care" refers to practices aligned with guidelines from the American Society for Reproductive Medicine.
• Other terms define "health insurance issuer" (entities offering health plans), "manufacturer" (producers of approved fertility-related drugs/devices), and "State" (includes all U.S. states, territories, and subdivisions).

• Statutory Rights (Section 4):
• Individuals have the right to receive fertility treatments, continue ongoing treatments, manage their reproductive materials (e.g., eggs, sperm, embryos), and enter contracts for their handling, without state interference that affects interstate commerce.
• Health care providers can choose to provide or assist with these treatments, including testing, storage, and disposition of materials.
• Health insurance issuers can opt to cover such treatments.
• Manufacturers can produce, import, market, and distribute FDA-approved drugs/devices for fertility purposes.
• States can enforce general health/safety laws only if they align with medical standards and cannot be met through less restrictive means.

• Enforcement Mechanisms (Section 4(c)):
• The U.S. Attorney General can sue states or officials enforcing conflicting laws, with courts required to invalidate violations.
• Private individuals/entities (including providers on behalf of patients) can file civil suits against state actors for injunctions and equitable relief (e.g., court orders to stop enforcement).
• Prevailing plaintiffs receive litigation costs and attorney fees; federal courts have jurisdiction, and cases can be removed from state courts.
• Providers can sue to protect themselves, staff, or patients.

• Rules of Construction and Violations (Section 4(d)):
• State actions violate the Act if they impose medically unnecessary requirements (e.g., extra visits or inaccurate information), restrict facilities/staffing beyond standards, discriminate based on marital status/sex/sexual orientation/gender identity, limit telemedicine or out-of-state access, mandate unsafe embryo transfers, or restrict medications/procedures like egg retrieval or cryopreservation.
• The list of violations is not exhaustive; novel restrictions could also qualify.
• Compliance with FDA regulations is explicitly allowed and does not violate the Act.

• Applicability and Preemption (Section 5):
• The Act preempts (overrides) conflicting state laws, rules, or enforcement, whether enacted before or after the bill.
• Exceptions: State laws resolving disputes over shared reproductive materials or protecting access to standard care (e.g., holding providers accountable for substandard treatment) remain valid if non-conflicting.
• Preserves federal laws on drugs/devices (e.g., FDA rules) and HIPAA privacy protections.
• The Act can be raised as a defense in lawsuits, and later federal laws apply unless they explicitly override it.

Significant Changes to Existing Law

• Introduces new federal protections specifically for fertility treatments, preempting state laws that single out or unduly burden these services, unlike current law where states have broad authority over medical practice and reproductive health.
• Creates explicit statutory rights tied to interstate commerce jurisdiction, shifting some control from states to federal enforcement.
• Expands private rights of action and AG intervention, similar to mechanisms in laws like the Reproductive Freedom for All Act, but tailored to IVF and assisted reproduction rather than abortion.
• Clarifies that FDA-compliant activities are shielded, preventing states from using non-FDA justifications to restrict fertility tools.

Potential Impacts

• On Citizens: Enhances access to fertility treatments nationwide, reducing barriers for individuals (e.g., same-sex couples, single parents, or those with medical infertility) by blocking state-level bans or delays, potentially increasing successful pregnancies and family-building options.
• On Government Agencies: Empowers the Department of Justice (via the Attorney General) to challenge state laws, increasing federal oversight of reproductive health; the Department of Health and Human Services gains authority to define additional fertility services. States may face litigation costs and need to revise conflicting regulations.
• On Health Care and Insurance: Providers and insurers gain freedom to offer/cover services without state penalties, likely expanding availability but requiring adaptation to federal standards.
• On International Relations: No direct impacts mentioned; the bill focuses on domestic commerce and does not address cross-border fertility services or global trade in reproductive materials.

Main Stakeholders Affected

• Individuals Seeking Fertility Treatment: Primary beneficiaries, including patients pursuing IVF, egg/sperm donation, or preservation, who gain protected rights to choose and access care.
• Health Care Providers: Doctors, clinics, and support staff offering fertility services, protected from state licensing revocations or operational restrictions.
• Health Insurance Issuers: Companies providing coverage, enabled to include fertility benefits without state mandates or bans.
• Manufacturers: Pharmaceutical and device companies producing fertility-related products (e.g., IVF drugs, cryopreservation tools), shielded from state marketing/sales limits.
• States and Local Governments: Potentially restricted in regulating fertility care, facing lawsuits if laws conflict, but allowed to maintain neutral health/safety standards.
• Federal Agencies: U.S. Attorney General, HHS Secretary, and FDA, tasked with enforcement, definitions, and preserving existing regulatory roles.

Notable Legal, Constitutional, or Political Implications

• Legal: Establishes strong preemption of state laws under the Supremacy Clause, with robust enforcement tools (e.g., injunctions, fee-shifting) that could lead to frequent federal-state litigation; private actions empower affected parties without needing administrative exhaustion.
• Constitutional: Relies on Congress's Commerce Clause authority to regulate interstate activities (e.g., travel for treatment, drug distribution), potentially inviting challenges if seen as overreaching into traditional state medical regulation; protects against discrimination on federally protected grounds like sex and gender identity, aligning with Equal Protection principles.
• Political: Advances reproductive rights in a post-Roe v. Wade landscape by focusing on fertility (not abortion), introduced by a bipartisan but largely Democratic group of senators; could polarize debates on "personhood" laws affecting embryos, influencing future elections and state-federal tensions over family policy.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Sen. Duckworth, Tammy [D-IL]

Cosponsors (35)

Sen. Murray, Patty [D-WA], Sen. Booker, Cory A. [D-NJ], Sen. Schumer, Charles E. [D-NY], Sen. Reed, Jack [D-RI], Sen. Warren, Elizabeth [D-MA], Sen. Padilla, Alex [D-CA], Sen. Welch, Peter [D-VT], Sen. Cantwell, Maria [D-WA], Sen. Fetterman, John [D-PA], Sen. Hickenlooper, John W. [D-CO], Sen. Merkley, Jeff [D-OR], Sen. Schatz, Brian [D-HI], Sen. Warner, Mark R. [D-VA], Sen. Klobuchar, Amy [D-MN], Sen. Alsobrooks, Angela D. [D-MD], Sen. Coons, Christopher A. [D-DE], Sen. King, Angus S., Jr. [I-ME], Sen. Blumenthal, Richard [D-CT], Sen. Whitehouse, Sheldon [D-RI], Sen. Sanders, Bernard [I-VT], Sen. Peters, Gary C. [D-MI], Sen. Gallego, Ruben [D-AZ], Sen. Durbin, Richard J. [D-IL], Sen. Heinrich, Martin [D-NM], Sen. Hirono, Mazie K. [D-HI], Sen. Shaheen, Jeanne [D-NH], Sen. Rosen, Jacky [D-NV], Sen. Murphy, Christopher [D-CT], Sen. Gillibrand, Kirsten E. [D-NY], Sen. Baldwin, Tammy [D-WI], Sen. Kaine, Tim [D-VA], Sen. Ossoff, Jon [D-GA], Sen. Schiff, Adam B. [D-CA], Sen. Bennet, Michael F. [D-CO], Sen. Slotkin, Elissa [D-MI]

Recent Actions

• 2025-06-11: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
• 2025-06-11: Introduced in Senate

Bill Versions

• Protect IVF Act — issued 2025-06-11 — PDF (20 pages)